Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Church & Dwight Co., Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Church & Dwight Co., Inc. trades at $102.84 (market cap $24.38B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays a 1.2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CHD | |
|---|---|---|
Market Cap | $29.60B | $24.38B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $105.26 |
52-Week Low | $205.48 | $81.60 |
Enterprise Value | $27.56B | $26.38B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Church & Dwight (CHD) trades at $101.56, down 1.68% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results with 5.8% organic sales growth, beating expectations, and raised full-year guidance. Valuation ratios are elevated with a P/E of 32.94, while profitability remains solid with a net income margin of 11.96%.
Outlook is positive driven by volume growth and market share gains, but risks include high valuation and competitive pressures. Analysts are bullish with a $103.57 consensus target, offering modest upside from current levels amid steady cash flows and dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
